Dec 15, 2010 by Brian Orelli, PhDBeautiful Efficacy, Wrong PillLexicon gets hit with the placebo effect.
Dec 14, 2010 by Brian Orelli, PhD3 Ways to Play Biotech With OptionsThe road to riches doesn't have to be risky.
Dec 14, 2010 by Brian Orelli, PhDAnother Mishap for a Drugmaker That Can't Afford ItEli Lilly puts cancer drug tasisulam on a clinical hold.
Dec 14, 2010 by Brian Orelli, PhDAn Ounce of Prevention, a Pound of Blockbuster SalesAmgen's Xgeva delays bone metastasis.
Dec 13, 2010 by Brian Orelli, PhDYep, We Still Want to Lowball YouStock holders aren't falling for it.
Dec 10, 2010 by Brian Orelli, PhDSomething Is Better Than Nothing, I GuessNovartis' Zometa fails a critical clinical trial.
Dec 8, 2010 by Brian Orelli, PhDWinners and Losers at the Hematology Society MeetingNot every blood-cancer drug can make it.
Dec 7, 2010 by Brian Orelli, PhDHow Pfizer's New Chief Can Right the ShipBigger is not always better.
Dec 3, 2010 by Brian Orelli, PhDMerck Smartens UpThe acquisition of SmartCells looks like an intelligent move.
Dec 3, 2010 by Brian Orelli, PhDObesity Drug Companies Are (Still) RiskyOrexigen heads before an FDA panel.
Dec 2, 2010 by Brian Orelli, PhDA Short FDA Delay. For What?GlaxoSmithKline and Valeant aren't saying.
Dec 2, 2010 by Brian Orelli, PhDAn Ounce of Prevention Gets Shot DownAn FDA panel shoots down Merck's and Glaxo's prostate drugs.
Dec 1, 2010 by Brian Orelli, PhDWe're Still Buying. Probably.Despite manufacturing problems, J&J continues with its purchase of Crucell.
Nov 30, 2010 by Brian Orelli, PhDRNAi Is On SaleThe novel technology looks more promising at these prices.
